Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia

Annals of the New York Academy of Sciences

Volumn 903, Issue , 2000, Pages 497-500

  Clarke, R ^a,b   Joachim, C ^b   Esiri, M ^b   Morris, J ^b   Bungay, H ^b   Molyneux, A ^b   Budge, M ^b   Frost, C ^a   King, E ^b   Barnetson, L ^b   Smith, A D ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CORRELATION FUNCTION; DEMENTIA; DEPENDENT PERSONALITY DISORDER; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LEUKOARAIOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PREVALENCE; REGISTER; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0034017958     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06405.x     Document Type: Conference Paper

References (11)

1. 1. SNOWDEN, D.A., L.H. GREINER, J.A. MORTIMER, K.P. RILEY, P.A. GREINER & W.R. MARKESBERY. 1997. Brain infarction and the clinical expression of Alzheimer's disease: the Nun Study. JAMA 277: 813-817.
2. 2. NAGY, Z.S., M.M. ESIRI, K.A. JOBST, et al. 1997. The effects of additional pathology on the cognitive deficit of Alzheimer's disease. J. Neuropathol. Exp. Neurol. 56: 165-170.
3. 3. INZITARI, D., F. DIAZ, A. Fox, V.C. HACKINSKI, A. STEINGART, C. LAU, A. DONALD, et al. 1987.Vascular risk factors and leuko-araiosis. Arch. Neurol. 44: 42-44.
4. 4. BRUN, A. & E. ENGLAND. 1986. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19: 253-262.
5. 5. PANTONI, L. & J.H. GARCIA. 1997. Pathogenesis of leukaraiosis: a review. Stroke 28: 652-659.
6. 6. JOBST, K.A., A.D. SMITH, M. SZATMARI, et al. 1994. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 343: 829-830.
7. 7. JOBST, K.A., A.D. SMITH, M. SZATMARI, et al. 1992. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 340: 1179-1183.
8. 8. MIRRA, S.S., A. HEYMAN, D. MCKEEL, et al. 1991. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 2. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
9. 9. CLARKE, R., A.D. SMITH, K.A. JOBST, H. REFSUM, L. SUTTON & P.M. UELAND. 1998. Folate, vitamin B-12 and serum total homocysteine levels in confirmed Alzheimer's disease. Arch. Neurol. 55: 1449-1455.
10. 10. CLARKE, R., P. WOODHOUSE, A. ULVIK, et al. 1998. Variability and determinants of plasma total homocysteine levels in an elderly population. Clin. Chem. 44: 102-107.
11. 11. CLARKE, R., C. FROST, V. LEROY & R. COLLINS for the Homocysteine Lowering Trialist's collaboration. 1998. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialist's Collaboration. Br. Med. J. 316: 894-898.